Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis.

Objective: To estimate the risk of progressive multifocal leukoencephalopathy (PML) and the safety of natalizumab administration in patients with relapsing-remitting multiple sclerosis (RRMS).

Methods: A descriptive retrospective observational study including all patients with RRMS treated with natalizumab followed-up after 10 years.The likelihood of developing PML was estimated based on three risk factors: anti-John Cunningham virus antibody index, previous immunosuppressive therapy, and duration of treatment.

Alemtuzumab for relapsing multiple sclerosis in clinical practice: A four-year retrospective one-center study.

Background: Disease-modifying therapies for multiple sclerosis have been developed tremendously over the last two decades.

Objective: The aim of this study was to review the short-, medium-, and long-term safety of alemtuzumab in relapsing remitting multiple sclerosis (RRMS).

Method: This retrospective observational study (2015-2019) included all patients with highly active or rapidly progressing and aggressive RRMS who were treated with alemtuzumab at the Cabueñes University Hospital.